Roni Mamluk Sells 10,000 Shares of Chiasma Inc (CHMA) Stock

Chiasma Inc (NASDAQ:CHMA) Director Roni Mamluk sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $5.31, for a total value of $53,100.00. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $53,100. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Roni Mamluk also recently made the following trade(s):

  • On Tuesday, March 5th, Roni Mamluk sold 5,000 shares of Chiasma stock. The stock was sold at an average price of $5.00, for a total value of $25,000.00.
  • On Tuesday, January 22nd, Roni Mamluk sold 5,000 shares of Chiasma stock. The stock was sold at an average price of $3.67, for a total value of $18,350.00.

CHMA stock opened at $6.20 on Friday. The company has a market capitalization of $180.93 million, a P/E ratio of -4.84 and a beta of 1.57. Chiasma Inc has a 1 year low of $1.20 and a 1 year high of $7.19.

Chiasma (NASDAQ:CHMA) last issued its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.02). As a group, equities analysts forecast that Chiasma Inc will post -1.24 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in CHMA. Vanguard Group Inc increased its holdings in shares of Chiasma by 42.8% during the 3rd quarter. Vanguard Group Inc now owns 324,625 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 97,272 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Chiasma by 42.8% during the 3rd quarter. Vanguard Group Inc. now owns 324,625 shares of the biotechnology company’s stock worth $1,169,000 after buying an additional 97,272 shares during the last quarter. Tibra Equities Europe Ltd acquired a new stake in shares of Chiasma during the 1st quarter worth $200,000. Dimensional Fund Advisors LP boosted its position in Chiasma by 51.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 80,986 shares of the biotechnology company’s stock worth $292,000 after purchasing an additional 27,505 shares during the period. Finally, Citadel Advisors LLC boosted its position in Chiasma by 100.6% during the 3rd quarter. Citadel Advisors LLC now owns 35,656 shares of the biotechnology company’s stock worth $128,000 after purchasing an additional 17,881 shares during the period. Institutional investors and hedge funds own 64.48% of the company’s stock.

Several research analysts have recently commented on CHMA shares. ValuEngine upgraded Chiasma from a “hold” rating to a “buy” rating in a research report on Tuesday, March 5th. Roth Capital assumed coverage on Chiasma in a research report on Tuesday, February 19th. They set a “buy” rating and a $16.00 target price on the stock. HC Wainwright assumed coverage on Chiasma in a research report on Thursday, February 14th. They set a “buy” rating and a $11.00 target price on the stock. Brookline Capital Management restated a “buy” rating on shares of Chiasma in a research report on Wednesday, February 6th. Finally, Zacks Investment Research raised Chiasma from a “sell” rating to a “hold” rating in a report on Thursday, May 2nd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $10.95.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.baseballdailydigest.com/news/2019/05/10/chiasma-inc-chma-director-sells-53100-00-in-stock.html.

About Chiasma

Chiasma, Inc, a clinical-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease in the United States, Europe, and internationally. The company offers oral octreotide capsules for adult patients under the MYCAPSSA name, which is in two Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Recommended Story: Quick Ratio

Insider Buying and Selling by Quarter for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.